Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Mar;36(3):598–602. doi: 10.1128/aac.36.3.598

Effects of cefetamet (Ro 15-8074) on Treponema pallidum and experimental syphilis.

T J Fitzgerald 1
PMCID: PMC190562  PMID: 1622168

Abstract

Cefetamet pivoxil (Ro 15-8075) is a newly developed, expanded-spectrum cephalosporin that is orally active. In vitro, the active form, cefetamet (Ro 15-8074), at a concentration of 0.05 micrograms/ml killed and lysed Treponema pallidum. Rabbit serum did not diminish its effectiveness. The antibiotic rapidly entered the circulation following intramuscular injection into rabbits, attaining its highest levels of 24 to 37 micrograms/ml within 10 to 30 min. Animals were infected intradermally with T. pallidum and then treated with different doses of cefetamet. Accelerated healing was detected following treatment with 15 and 30 mg/kg of body weight. The antibiotic was also effective in killing organisms that had disseminated to distant tissues. In three separate sets of experiments, rabbits were infected with treponemes and then treated with cefetamet intramuscularly at 1, 15, or 30 mg/kg as follows: (i) after lesions had just become clinically apparent, (ii) after lesions were enlarged and well developed, or (iii) prior to the appearance of clinical lesions. Antibiotic effectiveness was determined by sacrificing the animals 1 week after antibiotic treatment and examining splenic tissue for residual, disseminated treponemes. Cefetamet was treponemicidal in all three situations. Maximum effects occurred when the antibiotic was injected before lesions had become clinically apparent (incubation period). These results suggest that cefetamet pivoxil might be useful for treating syphilitic infections.

Full text

PDF
600

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angehrn P., Hohl P., Then R. L. In vitro antibacterial properties of cefetamet and in vivo activity of its orally absorbable ester derivative, cefetamet pivoxil. Eur J Clin Microbiol Infect Dis. 1989 Jun;8(6):536–543. doi: 10.1007/BF01967476. [DOI] [PubMed] [Google Scholar]
  2. Bernstein-Hahn L., Valdés E., Gehanno P., Giamarellou H., Lassus A., Ulmer W. T., Vetter N., Walhor F., Wettengel R., Fernex M. Clinical experience with 1000 patients treated with cefetamet pivoxil. Curr Med Res Opin. 1989;11(7):442–452. doi: 10.1185/03007998909115931. [DOI] [PubMed] [Google Scholar]
  3. Berry C. D., Hooton T. M., Collier A. C., Lukehart S. A. Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection. N Engl J Med. 1987 Jun 18;316(25):1587–1589. doi: 10.1056/NEJM198706183162507. [DOI] [PubMed] [Google Scholar]
  4. Bowie W. R., Shaw C. E., Chan D. G., Black W. A. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 Mar;31(3):470–472. doi: 10.1128/aac.31.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chau P. Y., Leung Y. K., Ng W. W., Arnold K. Comparative in vitro antibacterial activities of two new oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). Antimicrob Agents Chemother. 1987 Mar;31(3):473–476. doi: 10.1128/aac.31.3.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fitzgerald T. J. Syphilis vaccine: up-regulation of immunogenicity by cyclophosphamide, Ribi adjuvant, and indomethacin confers significant protection against challenge infection in rabbits. Vaccine. 1991 Apr;9(4):266–272. doi: 10.1016/0264-410x(91)90110-r. [DOI] [PubMed] [Google Scholar]
  7. Johns D. R., Tierney M., Felsenstein D. Alteration in the natural history of neurosyphilis by concurrent infection with the human immunodeficiency virus. N Engl J Med. 1987 Jun 18;316(25):1569–1572. doi: 10.1056/NEJM198706183162503. [DOI] [PubMed] [Google Scholar]
  8. MILLER J. N. THE APPEARANCE AND PERSISTENCE OF VDRL, RPCF, AND TPI ANTIBODY DURING THE COURSE AND TREATMENT OF EXPERIMENTAL SYPHILIS IN THE RABBIT. J Invest Dermatol. 1964 May;42:367–371. doi: 10.1038/jid.1964.80. [DOI] [PubMed] [Google Scholar]
  9. Tam Y. K., Kneer J., Dubach U. C., Stoeckel K. Pharmacokinetics of cefetamet pivoxil (Ro 15-8075) with ascending oral doses in normal healthy volunteers. Antimicrob Agents Chemother. 1989 Jun;33(6):957–959. doi: 10.1128/aac.33.6.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Wyss R., Bucheli F. Determination of cefetamet and its orally active ester, cefetamet pivoxyl, in biological fluids by high-performance liquid chromatography. J Chromatogr. 1988 Aug 19;430(1):81–92. doi: 10.1016/s0378-4347(00)83136-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES